Delcath Systems, Inc.: Business Overview, Financials & Competitive Analysis
Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products include HEPZATO KIT and CHEMOSAT Hepatic Delivery System for M...
Cyborg Score thesis
Emerging interventional oncology player with validated hepatic delivery technology, growing adoption metrics, and regulatory...
Read the full analyst-debate transcript →Get the Latest Delcath Systems, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeDelcath Systems, Inc. Overview
Pro stress-test →Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products include HEPZATO KIT and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure.
Strategic Profile
Pro stress-test →The company achieved approximately 30% HEPZATO volume growth in Q2 2026 compared to Q2 2025. In April 2026, CHEMOSAT was included as a recommended liver-directed regional therapy option in the ESMO–EURACAN Clinical Practice Guideline for uveal melanoma, expanding clinical validation and market positioning in oncology.
Competitive Landscape
Pro stress-test →Sirtex Medical is identified as a competitor in hepatic delivery and regional liver cancer therapy. The interventional oncology space includes other regional therapy platforms and systemic immunotherapy combinations, but Delcath's drug-device combination and proprietary hepatic delivery system provide differentiation in controlling systemic chemotherapy exposure.
Industry Context
Delcath Systems, Inc. operates in Robotic Surgery.
Key facts
Founded: 1988 · Headquarters: Queensbury, NY, US · Revenue: $70.2M trailing twelve-month revenue (as of June 30, 2025) · Market cap: $373M (as of September 2025)